Profile data is unavailable for this security.
About the company
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
- Revenue in USD (TTM)6.35bn
- Net income in USD1.05bn
- Incorporated2021
- Employees10.00k
- LocationOrganon & Co30 Hudson Street, Fl 33JERSEY CITY 07302United StatesUSA
- Phone+1 (551) 430-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.organon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Plc | 1.73bn | 599.95m | 4.11bn | 2.10k | 6.93 | 3.27 | 6.18 | 2.38 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Alpine Immune Sciences Inc | 58.88m | -32.18m | 4.25bn | 142.00 | -- | 11.93 | -- | 72.18 | -0.6827 | -0.6827 | 1.18 | 5.43 | 0.1767 | -- | 210.65 | 414,619.70 | -9.66 | -21.93 | -11.36 | -27.81 | -- | -- | -54.66 | -170.16 | -- | -- | 0.00 | -- | 95.84 | 142.30 | 44.28 | -- | -0.3253 | -- |
Immunovant Inc | 0.00 | -243.45m | 4.32bn | 164.00 | -- | 6.34 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
Nuvalent Inc | 0.00 | -126.22m | 4.36bn | 92.00 | -- | 6.17 | -- | -- | -2.16 | -2.16 | 0.00 | 10.94 | 0.00 | -- | -- | 0.00 | -20.78 | -- | -21.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 4.40bn | 376.00 | -- | 5.03 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Krystal Biotech Inc | 95.95m | 57.16m | 4.53bn | 229.00 | 84.34 | 5.67 | 71.36 | 47.17 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 5.16bn | 702.00 | -- | 19.34 | -- | 9.84 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
Organon & Co | 6.35bn | 1.05bn | 5.27bn | 10.00k | 5.03 | 109.32 | 4.09 | 0.831 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
BridgeBio Pharma Inc | 218.60m | -538.26m | 5.38bn | 550.00 | -- | -- | -- | 24.59 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Immunitybio Inc | 622.00k | -583.20m | 5.46bn | 628.00 | -- | -- | -- | 8,773.17 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 5.57bn | 373.00 | 20.79 | 66.31 | 15.30 | 6.72 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.76bn | 927.00 | -- | 19.41 | -- | 7.41 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Revolution Medicines Inc | 4.57m | -484.27m | 6.18bn | 411.00 | -- | 3.58 | -- | 1,353.21 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Exelixis Inc | 1.85bn | 205.05m | 6.34bn | 1.31k | 33.65 | 3.02 | 27.52 | 3.43 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 31.15m | 12.19% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 30.14m | 11.79% |
Massachusetts Financial Services Co.as of 31 Dec 2023 | 10.21m | 3.99% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 9.44m | 3.69% |
Sound Shore Management, Inc.as of 31 Dec 2023 | 4.68m | 1.83% |
Nordea Investment Management AB (Denmark)as of 31 Mar 2024 | 3.97m | 1.55% |
Geode Capital Management LLCas of 31 Dec 2023 | 3.90m | 1.53% |
Slate Path Capital LPas of 31 Dec 2023 | 3.58m | 1.40% |
Citadel Advisors LLCas of 31 Dec 2023 | 3.45m | 1.35% |
Nordea Investment Management ABas of 28 Mar 2024 | 3.37m | 1.32% |